Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Tralokinumab is a monoclonal antibody that specifically neutralizes interleukin (IL)-13, a key driver of skin inflammation and barrier abnormalities in atopic dermatitis (AD). This study evaluated early and 2-year impacts of IL-13 neutralization on skin and serum biomarkers following tralokinumab treatment in adults with moderate-to-severe AD.
Methods: Skin biopsies and blood samples were evaluated from a subset of patients enrolled in the Phase 3 ECZTRA 1 (NCT03131648) and the long-term extension ECZTEND (NCT03587805) trials. Gene expression was assessed by RNA sequencing; protein expression was assessed by immunohistochemistry and immunoassay.
Results: Tralokinumab improved the transcriptomic profile of lesional skin by Week 4. Mean improvements in the expression of genes dysregulated in AD were 39% at Week 16 and 85% at 2 years with tralokinumab, with 15% worsening at Week 16 with placebo. At Week 16, tralokinumab significantly decreased type 2 serum biomarkers (CCL17/TARC, periostin, and IgE), reduced epidermal thickness versus placebo, and increased loricrin coverage versus baseline. Two years of tralokinumab treatment significantly reduced expression of genes in the Th2 (IL4R, IL31, CCL17, and CCL26), Th1 (IFNG), and Th17/Th22 (IL22, S100A7, S100A8, and S100A9) pathways as well as increased expression of epidermal differentiation and barrier genes (CLDN1 and LOR). Tralokinumab also shifted atherosclerosis signaling pathway genes (SELE, IL-37, and S100A8) toward non-lesional expression.
Conclusion: Tralokinumab treatment improved epidermal pathology, reduced systemic markers of type 2 inflammation, and shifted expression of key AD biomarkers in skin towards non-lesional levels, further highlighting the key role of IL-13 in the pathogenesis of AD.
Clinical Trial Registration: NCT03131648, NCT03587805.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/all.16108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a questionnaire for the detection of flares in atopic dermatitis treated with biologics and small molecules: a pilot study.
Ital J Dermatol Venerol
August 2025
Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy.
Background: Proper identification and management of flare in atopic dermatitis (AD) is complex, especially in patients being treated with biological drug or small molecules. To date, the definition of flare is not agreed upon. Available scores such as the ADCT (AD control tool) are administered retrospectively to the patient and do not cover key aspects such as self-medication with topical steroids.
View Article and Find Full Text PDFReal-World Clinical Practice Evaluation of Tralokinumab in Atopic Dermatitis: A 52-Week Multi-Center Retrospective Study in the Basque Country.
J Clin Med
August 2025
Dermatology Department, Hospital Universitario Cruces, 48903 Barakaldo, Spain.
: Tralokinumab is an anti-IL-13 monoclonal antibody approved for moderate-to-severe atopic dermatitis (AD). While pivotal trials have demonstrated its efficacy, real-world data remain limited. : We conducted a retrospective, multi-center study in the Basque Country including 109 adults with moderate-to-severe AD treated with tralokinumab.
View Article and Find Full Text PDFTargeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics.
Curr Issues Mol Biol
August 2025
Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by immune dysregulation and epidermal barrier dysfunction. Advances in understanding the interplay of genetic predisposition, cytokine signaling, and environmental triggers have led to the emergence of targeted therapies. Although biologic agents such as dupilumab, tralokinumab, and lebrikizumab have revolutionized AD management, their high costs, injectable administration, and limited global accessibility highlight the need for alternative options.
View Article and Find Full Text PDFSafety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trials.
Br J Dermatol
August 2025
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA.
Background: Patients with moderate-to-severe atopic dermatitis (AD) require long-term management, and understanding the long-term safety of new treatments is a top priority for patients and healthcare professionals.
Objectives: To evaluate the safety of tralokinumab in adults and adolescents with moderate-to-severe AD by conducting an integrated safety analysis of 7 placebo-controlled trials and the ongoing, open-label extension study ECZTEND.
Methods: An initial 16-week placebo-controlled (PBO-CTRL) safety set and an all-tralokinumab (ALL-TRALO) safety set combining the placebo-controlled trials and ECZTEND (data cut-off 30 April, 2022) were analyzed.
Conjunctivitis secondary to novel systemic dermatologic agents: a growing concern.
Curr Opin Ophthalmol
August 2025
Department of Ophthalmology, University of Washington School of Medicine, Seattle, Washington, USA.
Purpose Of Review: This review aims to summarize current knowledge on ocular surface side effects associated with novel systemic therapies for atopic dermatitis (AD) and psoriasis.
Recent Findings: Interleukin inhibiting monoclonal antibodies such as dupilumab and tralokinumab, along with small molecule JAK-STAT inhibitors such as upadacitinib and abrocitibib, have revolutionized the treatment of AD and psoriasis. Despite their effectiveness in disease control, these agents have been increasingly associated with ocular adverse events, particularly conjunctivitis.